Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trialBruce E. Sands, Olga Fedorishina, Stephen B. Hanauer et al.|The Lancet|2022Cited by 295
The PROSIT-BIO CohortGionata Fiorino, Vito Annese, Natalia Manetti et al.|Inflammatory Bowel Diseases|2017Cited by 126
Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune‐mediated inflammatory diseases: A European retrospective observational studyLaurent Goessens, Jean‐Frédéric Colombel, An Outtier et al.|United European Gastroenterology Journal|2021Cited by 71
Six-Day or Seven-Day Regimens with Ranitidine Bismuth Citrate plus High-Dose Clarithromycin and Tinidazole Are Both Effective Against Helicobacter pylori InfectionGiovanni Cammarota, Giovanni Gasbarrini, O Cannizzaro et al.|Digestive Diseases and Sciences|1999Cited by 6
130 Efficacy and Safety of Obefazimod in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Two, Phase 3, Randomised, Double-Blind, Placebo-Controlled, 8-Week Induction Trials (ABTECT-1 and 2)Bruce E. Sands, Séverine Vermeire, Silvio Danese et al.|The American Journal of Gastroenterology|2025Cited by 1